This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
== Absorption bands == IR spectroscopy is often used to identify structures because functional groups give rise to characteristic bands both in terms of intensity and position (frequency). The positions of these bands are summarized in correlation tables as shown below.
This iconography also makes a striking parallel between hunting and combat, which are treated on an identical footing. The tombs would have been made during the lifetime of the dynast, and illustrated his deeds during his life. Given the date and circumstance of this sarcophagus, the dynast who is illustrated in the hunting and fighting scene may have been related to the Satrap of Hellespontine Phrygia, Pharnabazus, who fought again the Greeks on several occasions, particularly against Agesilaos when the latter attacked and ravaged the area around Daskyleion in 395 BCE. The bones found in the tomb belonged to a male of considerable strength, between 170 and 175 centimetres (67 and 69 in) in height, who died between 25 and 28 years old. He suffered a fall from a considerable height, probably from his horse during combat, many of his limbs having been crushed. He lived for several more years as a cripple, his limbs remaining misaligned, before dying. The sarcophagus could formerly be seen in the Çanakkale Archaeological Museum, where an earlier, 6th century BCE sarcophagus, the Polyxena sarcophagus, was also on display. Both are now located in the Troy Museum.
Plants that cause illness or death after consuming them are referred to as poisonous plants. The toxins in poisonous plants affect herbivores, and deter them from consuming the plants. Plants cannot move to escape their predators, so they must have other means of protecting themselves from herbivorous animals. Some plants have physical defenses such as thorns, spines and prickles, but by far the most common type of protection is chemical. Over millennia, through the process of natural selection, plants have evolved the means to produce a vast and complicated array of chemical compounds to deter herbivores. Tannin, for example, is a defensive compound that emerged relatively early in the evolutionary history of plants, while more complex molecules such as polyacetylenes are found in younger groups of plants such as the Asterales. Many of the known plant defense compounds primarily defend against consumption by insects, though other animals, including humans, that consume such plants may also experience negative effects, ranging from mild discomfort to death. Many of these poisonous compounds also have important medicinal benefits. The varieties of phytochemical defenses in plants are so numerous that many questions about them remain unanswered, including:
Sources: en.wikipedia.org
Crick was interested in two fundamental unsolved problems of biology: how molecules make the transition from the non-living to the living, and how the brain makes a conscious mind. He realised that his background made him more qualified for research on the first topic and the field of biophysics. In 1946 Crick read Erwin Schrödinger's book, What Is Life? and was influenced by it, and Linus Pauling, to switch from physics to biology. It was clear in theory that covalent bonds in biological molecules could provide the structural stability needed to hold genetic information in cells. It only remained as an exercise of experimental biology to discover exactly which molecule was the genetic molecule. In Crick's view, Charles Darwin's theory of evolution by natural selection, Gregor Mendel's genetics and knowledge of the molecular basis of genetics, when combined, revealed the secret of life. Crick had the very optimistic view that life would very soon be created in a test tube. However, some people (such as fellow researcher and colleague Esther Lederberg) thought that Crick was unduly optimistic. It was clear that some macromolecule such as a protein was likely to be the genetic molecule. However, it was well known that proteins are structural and functional macromolecules, some of which carry out enzymatic reactions of cells. In the 1940s, some evidence had been found pointing to another macromolecule, DNA, the other major component of chromosomes, as a candidate genetic molecule.
Global Security Weapons and Complex Integration National Ignition Facility and Photon Science Operations and Business Business Facilities & Infrastructure Institutional Facilities Management Integrated Safety Management System Project Office Nuclear Operations Planning and Financial Management Staff Relations Strategic Human Resources Management Three other directorates are each headed by a principal associate director who reports to the LLNL director:
It chose to follow a single character to aid the immersion, creating the isolation of a vampire unable to trust any other character. This aided the story and compensated for the technical issues of allowing multiple player characters. Choice is a significant aspect of the game, requiring a non-linear design to accommodate the customized characters. Level design began with a list of factors such as Disciplines, stealth, and feats. Each area had to be viable for a shooting character (sufficient ammunition), a discipline-focused character (sufficient blood sources to keep the powers fueled), and a melee specialist (to reach enemies without being killed), with stealth options and option combinations. Level design began with a focus on stealth, considering the positioning of guards and the character's potential stealth capability at that point in the game. Then direct, combat-heavy, and dialogue paths were added. The amusement arcade area was to feature playable versions of Activision arcade games such as Pitfall!, though the idea was abandoned due to time constraints. Director Leonard Boyarsky considered the animation system important in the team's choice of the Source engine. The integrated "faceposer" tool allowed Troika to customize facial animations, expressions, gestures, and lip-synching, eliminating the need to explain what a character was doing. Every non-player character required a voiceover, which helped Troika define its characters more quickly.
{\displaystyle {\begin{aligned}{\frac {D\omega _{i}}{Dt}}&={\frac {\partial \omega _{i}}{\partial t}}+v_{j}{\frac {\partial \omega _{i}}{\partial x_{j}}}\\&=\omega _{j}{\frac {\partial v_{i}}{\partial x_{j}}}-\omega _{i}{\frac {\partial v_{j}}{\partial x_{j}}}+e_{ijk}{\frac {1}{\rho ^{2}}}{\frac {\partial \rho }{\partial x_{j}}}{\frac {\partial p}{\partial x_{k}}}+e_{ijk}{\frac {\partial }{\partial x_{j}}}\left({\frac {1}{\rho }}{\frac {\partial \tau _{km}}{\partial x_{m}}}\right)+e_{ijk}{\frac {\partial B_{k}}{\partial x_{j}}}\end{aligned}}}
Sources: en.wikipedia.org
=== Other interventions === A 2024 review found that fecal microbiota transplantation may reduce pain intensity and improve fatigue and quality of life in patients with fibromyalgia, but evidence was insufficient at that stage to support use. Research on gut microbiome links with FM continues. Hyperbaric oxygen therapy (HBOT) has shown beneficial effects in treating chronic pain by reducing inflammation and oxidative stress. However, treating fibromyalgia with hyperbaric oxygen therapy is still controversial, in light of the scarcity of large-scale clinical trials. In addition, hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it. An evaluation of nine trials with 288 patients in total found that HBOT was more effective at relieving fibromyalgia patients' pain than the control intervention. In most of the trials, HBOT improved sleep disturbance, multidimensional function, patient satisfaction, and tender spots. Negative outcomes (predominantly mild barotrauma (air pressure effect on ear or lung) that could be resolved spontaneously) were experienced by 24% of the patients, but they were not prevented from completing the treatment regimen, and no serious side effects, complications, or deaths were reported.
are constants fit from data. On the other hand, several authors express caution with respect to this model. Errors as large as 30% can be encountered using equation (1), compared with fitting equation (2) to experimental data. More fundamentally, the physical assumptions underlying equation (1) have been criticized. It has also been argued that the exponential dependence in equation (1) does not necessarily describe experimental observations more accurately than simpler, non-exponential expressions. In light of these shortcomings, the development of a less ad hoc model is a matter of practical interest. Foregoing simplicity in favor of precision, it is possible to write rigorous expressions for viscosity starting from the fundamental equations of motion for molecules. A classic example of this approach is Irving–Kirkwood theory. On the other hand, such expressions are given as averages over multiparticle correlation functions and are therefore difficult to apply in practice. In general, empirically derived expressions (based on existing viscosity measurements) appear to be the only consistently reliable means of calculating viscosity in liquids. Local atomic structure changes observed in undercooled liquids on cooling below the equilibrium melting temperature either in terms of radial distribution function g(r) or structure factor S(Q) are found to be directly responsible for the liquid fragility: deviation of the temperature dependence of viscosity of the undercooled liquid from the Arrhenius equation (2) through modification of the activation energy for viscous flow.
For one thing, because there is an extra NADPH-catalyzed reduction, this can contribute to depletion of cellular stores of NADPH and also reduce levels of alpha-ketoglutarate available to the cell. In particular, the depletion of NADPH is problematic because NADPH is highly compartmentalized and cannot freely diffuse between the organelles in the cell. It is produced largely via the pentose phosphate pathway in the cytoplasm. The depletion of NADPH results in increased oxidative stress within the cell as it is a required cofactor in the production of GSH, and this oxidative stress can result in DNA damage. There are also changes on the genetic and epigenetic level through the function of histone lysine demethylases (KDMs) and ten-eleven translocation (TET) enzymes; ordinarily TETs hydroxylate 5-methylcytosines to prime them for demethylation. However, in the absence of alpha-ketoglutarate this cannot be done and there is hence hypermethylation of the cell's DNA, serving to promote epithelial-mesenchymal transition (EMT) and inhibit cellular differentiation. A similar phenomenon is observed for the Jumonji C family of KDMs which require a hydroxylation to perform demethylation at the epsilon-amino methyl group. Additionally, the inability of prolyl hydroxylases to catalyze reactions results in stabilization of hypoxia-inducible factor alpha, which is necessary to promote degradation of the latter (as under conditions of low oxygen there will not be adequate substrate for hydroxylation).
as follows. They are calculated for the Gaussian distribution of asperities, which have been shown to be unrealistic for engineering surface but can be assumed where friction, load carrying capacity or real contact area results are not critical to the analysis.
Part of the WADA submission to the appeal, which the CAS accepted in its verdict, was that Thymosin Beta-4 was the only form of Thymosin which would have had the soft tissue recovery effect that Dank had attributed to it – text messages from Dank had specifically described Thymosin as the cornerstone of the soft tissue recovery program. Two urine samples taken from Essendon players during 2012 were also found to contain elevated Thymosin Beta-4; the levels were not high enough to fail the drug test, but they added to the cable of evidence against the players. Significantly, the CAS also determined that the players were "significantly at fault", disqualifying them from any penalty reduction. This was considered a surprise, as press throughout the entire saga had opined that by having followed the direction of club officials, the players would be found to have had no significant fault or negligence, qualifying them for a 50% penalty reduction. Key to this finding was the revelation that none of the eighteen different players who had been drug tested on a total of thirty occasions during the program had declared the supplements injections on their doping control forms, and that some had withheld information from the club doctor on Dank's instruction – revelations which damaged the credibility of other evidence put forward by the players.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.